# US 2012/0252858 A1 · Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252858 A1
- Document ID: US20120252858A1
- Status: Published application
- Kind: A1
- Application number: 13/456,691
- Filed: 2012-04-26
- Published: 2012-10-04
- Earliest claimed: 2007-10-31
- Assignees: Proteotech, Inc.
- Inventors: Luke A. Esposito; F. Michael Hudson; Thomas Lake; Joel Cummings; Manfred Weigele; Alan D. Snow; Lesley Larsen
- Web page: https://patentgrep.com/patent/US20120252858A1

## CPC

- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 37/16: by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
- C07C 39/10: Polyhydroxy benzenes; Alkylated derivatives thereof (C07C39/08 takes precedence)
- C07C 39/17: containing other rings in addition to the six-membered aromatic rings {, e.g. cyclohexylphenol}
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/54: having two double bonds between ring members or between ring members and non-ring members
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07C 2603/74: Adamantanes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

## Claims

### Claim 1

A compound having the formula:
where the hydroxyl groups are independently positioned and
R is an unsubstituted pyrazole, and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1 where the compound is 3,5-bis(3,4 dihydroxyphenyl) pyrazole and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 4 (depends on 1)

A method of inhibiting the formation, deposition, accumulation, or persistence of Aβ amyloid or α-synuclein aggregates, comprising treating the aggregates with an effect amount of the compound of claim 1.

### Claim 5 (depends on 1)

A method of inhibiting and/or relieving an amyloid disease or a synucleinopathy in a mammal suffering therefrom, comprising administration to the mammal of an effective amount of the compound of claim 1.

### Claim 6 (depends on 5)

The method of claim 5 where the β-amyloid disease is selected from the group of diseases consisting of Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, and cerebral β-amyloid angiopathy.

### Claim 7 (depends on 5)

The method of claim 5 where the β-amyloid disease is Alzheimer's disease.

### Claim 8 (depends on 5)

The method of claim 5 where the synucleinopathy is selected from the group consisting of Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, and the Parkinsonism-dementia complex of Guam.

### Claim 9 (depends on 5)

The method of claim 5 where the synucleinopathy is Parkinson's disease.

### Claim 10 (depends on 1)

A method for improving motor performance in a mammal suffering from a synucleinopathy, comprising administration to the mammal of an effective amount of the compound of claim 1.

### Claim 11 (depends on 1)

A method for arresting the progression of motor deficits in a mammal suffering from Parkinson's disease, comprising administration to the mammal of an effective amount of the compound of claim 1.

### Claim 12 (depends on 5)

The method of claim 5 where the mammal is a human.

### Claim 13 (depends on 5)

The method of claim 5 where the amount of the compound administered is between 0.1 mg/Kg/day and 1000 mg/Kg/day.

### Claim 14 (depends on 5)

The method of claim 5 where the amount of compound administered is between 1 mg/Kg/day and 100 mg/Kg/day.

### Claim 15 (depends on 5)

The method of claim 5 where the amount of compound administered is between 10 mg/Kg/day and 100 mg/Kg/day.
